We recently found that PD‐L1 antibody treatment can activate multiple oncogenic pathways such as Wnt/β‐catenin, Hedgehog, and HIF1 in a JMJD2D‐dependent manner,[8] which also contributes to the resistance of CRC to PD‐L1 antibody treatment. Here, CD274 is linked to colorectal carcinoma.